Welcome to the Lisata Therapeutics second quarter 2023 financial results and business update conference call. Currently, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ask a question at that time, please press star one one on your telephone. You will then hear an automated message advising you your hand is raised. As a reminder, the call is being recorded today, Tuesday, August 15th, 2023. I will now turn the call over to John Menditto, Vice President of Investor Relations and Corporate Communications at Lisata. Please go ahead, sir. Thank you, operator. Good morning, everyone. Welcome to Lisata's second quarter 2023 conference call to discuss our financial results and the opportunity to provide a business update. Joining me today from our management team are Dr. David Mazzo, President and Chief Executive Officer, Dr. Kristen Buck, Executive Vice President of Research and Development and Chief Financial Officer, and James Nisco, Vice President of Finance and Treasury. Yesterday, Monday, August 14th, we issued a press release after market trading close, announcing our second quarter 2023 financial results, which is available under the Investors and News section of the company website, along with the webcast replay of this call. If you have not received the news release or if you'd like to be added to the company's email distribution list, please email me at jmenditto@lisata.com. Before we begin, I remind you that comments made by management during this conference call will contain forward-looking statements that involve risks and uncertainties regarding the operations and future results of Lisata. I encourage you to review the company's filings with the Securities and Exchange Commission, including without limitations, its Forms 10-Q, 8-K, and 10-K, which identify specific risk factors that may cause actual results or events to differ materially from those described in the forward-looking statements. The content of this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, Tuesday, August 15th, 2023. Lisata undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call. With that, I'll now turn the call over to Dr. Mazzo. Dave? Thank you, John. Good morning, everyone. Thank you for joining us today as we provide an overview of recent business highlights, discuss our second quarter 2023 financial results, and give an update on the progress of our various development programs. I'm kicking off today's call with a heightened sense of excitement and optimism for the future of Lisata. During the second quarter, we continued the advancement of our clinical development programs for the treatment of advanced solid tumors. As those familiar with the company know, Lisata is a clinical-stage pharmaceutical company focused on the development of a novel solid tumor targeting and penetration technology to improve the efficacy of anticancer drugs. Our development portfolio contains programs that are designed to bring significant therapeutic improvement in the treatment of solid tumors in a pharmacoeconomically attractive paradigm. LSTA1, our lead product candidate, is the subject of multiple planned and ongoing clinical trials being conducted globally in a variety of solid tumor types and in combination with multiple anticancer agents of differing modalities. Based on substantial preclinical and, most importantly, early clinical data in humans, we believe that LSTA1 has the potential to become an integral part of a revised standard of care treatment regimen for many difficult-to-treat cancers. During this call, our Chief Medical Officer, Dr. Kristen Buck, will provide more specifics on our clinical programs following our review of financial results. However, before moving on to the financial and clinical overview, we are pleased to announce a significant milestone in the form of a technology transfer agreement of our Tumor-Penetrating Nanocomplex, or TPN platform, with Impilo Therapeutics, Inc., a recently formed company led by David Slack, former Lisata Chief Business Officer. The TPN platform targets intracellular delivery of RNA-based drugs to prevent solid tumor growth. TPN is designed so that it not only binds to proteins overexpressed on the surface of human cancer cells, but also passes through the membranes by way of a cell-penetrating peptide. Once inside the cells, the TPN is expected to release an RNA-based drug directed against the tumor. The noted technology transfer will place the TPN technology in the capable hands of a team with profound expertise in RNA-based therapeutics development, further enhancing its potential impact in the field. Under the terms of the technology transfer agreement, upon closing, Lisata will receive an equity stake in Impilo Therapeutics. Lisata will also receive a seat on Impilo's board of directors, but is not obliged to commit any capital or additional resources to the program's future development. With that, I now will turn the call over to James Nisco, our Vice President of Finance and Treasury, to review and provide commentary on our financial results. James? Thanks, Dave. Good morning, all. I'm pleased to join you today to present a summary of our second quarter 2023 financial results. Starting with operating expenses. Research and development expenses remained constant at approximately $3.2 million for the three months ended June 30th, 2023, and three months ended June 30th, 2022. Expenses this quarter were primarily due to study startup activities associated with the LSTA1 BOLSTER trial, enrollment activities for the LSTA1 ASCEND study, and Chemistry, Manufacturing, and Controls activities for LSTA1 to support all development activities. General and administrative expenses were approximately $3.7 million for the three months ended June 30th, 2023, compared to $3.5 million for the three months ended June 30th, 2022, representing an increase of $0.2 million or 6.5%. This was primarily due to severance costs associated with the elimination of the chief business officer position on May 1st, 2023, partially offset by non-recurring merger-related costs in the prior year. Overall, net losses were $4 million for the three months ended June 30th, 2023, compared to $6.6 million for the three months ended June 30, 2022. A decrease of approximately 40%, primarily due to $2.2 million in non-dilutive funding received as an approved participant of the Technology Business Tax Certificate Transfer Program, sponsored by the New Jersey Economic Development Authority. Turning now to our balance sheet and cash flow. As of June 30th, 2023, the company had cash, cash equivalents, and marketable securities of approximately $57.6 million. The company is confident that its projected capital will fund its current proposed operations into the first quarter of 2026, encompassing anticipated data milestones from all its ongoing and planned clinical trials. This completes my financial overview, and I will now turn the call over to our Chief Medical Officer, Dr. Kristen Buck, for the review of our clinical development pipeline. Kristen? Thank you, James, and good morning, everyone. As those that follow us know, Lisata's pipeline is built on a portfolio of proprietary and patented technology that is grounded in strong scientific rationale and a body of published preclinical and early clinical data. Our platform technology is designed to address major impediments to the successful treatment of advanced solid tumors in the context of increasing pharmacoeconomic pressures on the healthcare system. We appreciate the critical importance of generating meaningful clinical data to advance our platform technology, and I can assure you that our entire organization has this goal top of mind in everything we do. With that, I will now provide an overview of our lead product candidate, LSTA1, LSTA1, for the treatment of advanced solid tumors in combination with other anticancer agents. Despite advances in cancer therapy today, many solid tumors remain difficult to effectively treat. Cancers such as pancreatic cancer, gastric cancers, and other solid tumor cancers are surrounded by a dense fibrotic tissue known as the stroma, which limits access of most pharmacotherapies to the tumor. Many tumors also exhibit a hostile tumor microenvironment, or TME, which suppresses the patient's immune system and makes it less effective in fighting cancer. The combination of dense stroma and a hostile tumor microenvironment negatively impacts the ability of many cytotoxic agents and immunotherapies to effectively treat these cancers. This, coupled with the fact that most anticancer therapies are not efficient in targeting only cancer tissue, defines the major challenge of maximizing effectiveness and safety in the treatment of solid tumors. To combat this, Lisata's approach is to activate the C-end Rule or CendR system, a naturally occurring active transport system, to selectively deliver anticancer drugs through the stroma and into the tumor. Lisata's lead product candidate, LSTA1, is an investigational drug that actuates the CendR active transport mechanism while also having the potential to modify the tumor microenvironment and make it less immunosuppressive. LSTA1 targets tumor, vascular, endothelial cells, as well as tumor cells themselves, based on its affinity for αv, β3, and β5 integrins that are upregulated on, upregulated on these cells, but not on healthy tissue. LSTA1 is a nine amino acid, cyclic, internalizing iRGD peptide that, once bound to these integrins, is cleaved by protease. Proteases expressed in the tumor microenvironment to release a peptide fragment called the CendR fragment. The CendR fragment then has high affinity for and binds to an adjacent receptor called Neuropilin-1, also upregulated on tumor endothelial and tumor cells, to activate the C-end Rule active transport pathway and carry anticancer drugs more efficiently into solid tumors. Additionally, LSTA1 has been shown in a range of preclinical models to modify the tumor microenvironment, making it less hostile to immune cells and adding to the efficacy of anticancer drugs used against solid tumors. These results come internally from Lisata and from collaborators and research groups around the world, and have been the subject of over 300 scientific publications. Along with our collaborators, we have amassed significant non-clinical data demonstrating enhanced delivery of a range of emerging anticancer therapies, including immunotherapies and RNA-based therapeutics. Clinically, LSTA1 has demonstrated favorable safety, tolerability, and activity to enhance delivery of standard of care chemotherapy for patients with metastatic pancreatic cancer. Our development programs are designed to exploit the potential of LSTA1 to enhance a variety of anticancer treatment modalities in a range of solid tumors. Currently, LSTA1 is the subject of about a dozen planned or active clinical trials globally for the treatment of various solid tumors. Let me touch on a few of these individually. The ASCEND trial is a 155 patient, double-blind, randomized, placebo-controlled clinical trial evaluating LSTA1 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. The trial is being conducted at up to 40 sites in Australia and New Zealand, led by the Australasian Gastro-Intestinal Trials Group, or AGITG, in collaboration with the NHMRC Clinical Trials Centre at the University of Sydney. We originally projected enrollment completion by the second quarter of 2024. However, with the study nearly 75% enrolled, we could achieve last patient in sooner than that. Just recently, we, along with our clinical research partner, WARPNINE, treated our first five patients in the iLSTA trial in Australia, evaluating LSTA1 in combination with standard of care chemotherapy. That is gemcitabine and nab-paclitaxel chemotherapy and immunotherapy using durvalumab as a first-line treatment in locally advanced yet non-resectable pancreatic ductal adenocarcinoma. This is the first of several planned trials in which we are expanding the study of LSTA1's impact on existing therapies to include immunotherapies. We also expect enrollment completion in this trial by the second quarter of 2024. The company's BOLSTER trial of LSTA1 is a phase 2a placebo-controlled basket trial in the United States, Europe, Canada, and Asia, evaluating LSTA1 in combination with standards of care in solid tumors, including head and neck, esophageal, and cholangiocarcinoma. This trial includes both cytotoxic and immunotherapy standards of care. Enrollment is now open. However, we, like many others, are being impacted by the global cisplatin shortage, which is part of the standard of care regimen for cholangiocarcinoma patients. This has led to severe shortages of the drug, long delays in obtaining any available material, and unfortunately, price gouging by some suppliers, resulting in prices reaching hundreds of times of what cisplatin would normally cost. Despite these challenges, our team has identified and secured a supply of cisplatin sufficient, sufficient to the needs of the BOLSTER trial, and we expect this material in our hands and available to patients in our study within about one month. Once this requirement, this required component of BOLSTER's protocol is at the investigational sites, we look much forward to announcing the first patient treated in the cholangiocarcinoma arm. Next is the CENDIFOX trial, a phase 1b/2a open-label trial of LSTA1 in combination with neoadjuvant FOLFIRINOX-based therapies in pancreatic, colon, and appendiceal cancers. It continues to make steady progress with approximately 80% of the study enrolled. We expect enrollment completion by the 4th quarter of this year, with data readouts in 2024. This trial will provide us with post-treatment biopsy immunoprofiling data as well as long-term outcome data. LSTA1 is also currently being evaluated in combination with gemcitabine and nab-paclitaxel in a phase 1b/2a open label trial in China, led by our licensee in that territory, Qilu Pharmaceutical. During the 2023 ASCO annual meeting, Qilu Pharmaceutical presented an abstract showing preliminary data from the study, which corroborated previously reported findings from the phase 1b/2a trial of LSTA1 plus gemcitabine and nab-paclitaxel, conducted in Australia in patients with metastatic pancreatic ductal adenocarcinoma. Final data are expected by the end of the second quarter of 2024. iLSTA, a phase 1b/2a proof-of-concept, safety, and early efficacy study evaluating LSTA1 in combination with nivolumab and FOLFIRINOX as a first-line treatment in locally advanced, non-resectable gastroesophageal adenocarcinoma, is still pending initiation as a function of availability of funding by our partner, WARPNINE. We hope to have further update on timing related to the execution of the study by the end of the third quarter of this year. In addition to the ongoing clinical trials I just mentioned, we also plan to have other studies up and running in the next few months, including LSTA1 in combination with temozolomide and glioblastoma multiforme, commonly known as GBM. This study is designed as a phase 2a, double-blind, placebo-controlled, randomized proof of concept study evaluating LSTA1 when added to standard of care temozolomide, versus temozolomide and matching LSTA1 placebo in patients with newly diagnosed glioblastoma multiforme. It will be conducted across multiple sites in Estonia and Latvia. It is targeted to enroll 30 patients with a randomization of 2:1 LSTA1 plus standard of care versus placebo plus standard of care. Target for first patient treated is in the fourth quarter of 2023. Importantly, as recently announced, LSTA1 has been granted Orphan Designation by the U.S. Food and Drug Administration for malignant glioma. This action by FDA not only highlights the unmet medical need, but also recognizes the potential of LSTA1 to benefit patients in this, in this indication. Lastly, we are planning to study LSTA1 in combination with hyperthermic intraperitoneal chemotherapy, more commonly referred to as HIPEC, delivered via intraoperative intraperitoneal lavage in peritoneal carcinomatosis, a cancer that develops as a result of the contiguous spread of primary cancers such as ovarian, colorectal, and appendiceal, along the peritoneal layer. The study will be a phase 1, single center, unblinded, randomized controlled trial to determine the safety and tolerability of LSTA1, administered intraperitoneally in patients with peritoneal metastasis from colorectal, appendiceal, or ovarian cancer, undergoing cytoreductive surgery and HIPEC. 21 total patients will be randomized 2:1 to receive LSTA1 with HIPEC versus HIPEC alone after cytoreductive surgery. We anticipate that this study will also be up and running in the fourth quarter of 2023, and the first patient being treated shortly thereafter. For those who are interested, a more complete description of our trials will be available in the appendix section of the corporate presentation on our website. Additionally, in the body of the presentation, there are two milestone slides that depict the anticipated timing of key execution milestones and data re-readout for our trial. With that, I will now turn the call back to Dave. Thanks, Kristen. As we look back to the beginning of the year, even further to the status of development of LSTA1 in the clinic at the time of the formation of Lisata in September of 2022, it becomes immediately apparent that our team has made notable progress advancing this program according to the two pillars of our development strategy: rapid and focused development of LSTA1 in mPDAC, and broad application of LSTA1 in combination with a variety of anticancer agents applied to a variety of solid tumor types. We have designed our studies to be scientifically and medically rigorous and to provide results expeditiously, while also assuring that we are operating in a maximally capital-efficient manner. Now, with more than two years of capital available on our balance sheet, we believe we are well-placed to focus on the execution of our development plans and to achieve our goal of getting meaningful clinical data readouts as soon as possible. With that overview, operator, we're now ready to take questions. Thank you. As a reminder, to ask a question, please press star one one on your telephone. You will then hear an automated message advising that your hand is raised. Each listener will be permitted to ask 1 question at a time and will return to the queue for any additional questions. 1 moment for our first question in the queue. We have a question from Joseph Pantginis with HCWCO. Your line is open. Hi, good morning. Sara on for Joe taking the question. I was wondering, based on the brisk enrollment that you've seen, for the ASCEND, can you possibly gauge expectations, where we could expect a potential data readout? Thank you. Well, thanks, Sara. I appreciate your question. Good morning. You know, right now, the ASCEND trial protocol is very specific. It's a blinded trial with the two cohorts, as Kristen aptly described. You know, the current statistical analysis plan, it calls for a complete analysis and a data readout at the end of the trial. Based on current, you know, projections, let's just say the second quarter of 2024 to complete enrollment, we should expect, you know, a data readout sometime about one year to 18 months after that. I will say, however, we're looking at other means that might get us to some earlier data, and we'll be in a position to talk about those sometime during the fall. Of course, they do require agreement with our partners, AGITG and CTC in Australia, and we want to be sure that we don't compromise the integrity of the blinded study. Okay, thank you. Thank you. One moment for our next question. We have a question from Steve Brozak with WBB Securities. Your line is open. Yes, good morning, thanks for taking the questions. Given the fact that the patient profiles that you're looking at are really, really, seriously ill patients, what type of outcomes do you look at? 'Cause you're, you're looking at patients where the current standard of care can be very, very harmful, chemotoxins that are used on these patients. How would you judge outcomes that would be, let's say, optimal or even things that would be nontraditional as far as what you expect? I have one follow-up after that. Thank you. Well, thanks, Steve. Good morning. I'll, I'll answer the question generally, and then I'll turn to Kristen, who may be able to provide some additional specifics. Generally speaking, as you pointed out, let's use mPDAC as the example. You know, under current standard of care, you know, the, the median survival after diagnosis these days is, is still only around, you know, nine or so months, and, and less than, you know, 10% or so of the people diagnosed survive out to five years. It's a really devastating and lethal disease, even with the current chemotherapy treatments. We're looking to substantially improve that, of course, ultimately in cancer, while quality of life and, and progression-free survival are important endpoints, what we're looking to do ultimately is to extend overall survival in a meaningful way. Now I'll turn to Kristen to see if she'd like to provide some additional color. Thanks, Dave. I would only add a few caveats. We are definitely looking to improve overall survival as the patient populations, which we're studying, have horrible diagnoses and prognoses. While overall survival will predict their outcome, we're looking at progression-free survival, how long the patient stays well before their tumor progresses. The most important part is not enhancing the toxic side effects that these drugs have, because we're targeting the tumors. Instead of over-blasting the patient with cytotoxics, we're trying to target the tumors so the cytotoxics and immunotherapies are specifically going into the tumor. Therefore, Steve, we're looking to increase progression-free survival and overall survival without enhancing the toxic side effects of these standard of care drugs. Okay. It, it obviously makes sense. Along those same lines, you've, you've talked about, you've got a, a number of different partners, clinicians, researchers that are working with you across the globe. How, how would you categorize the level of interest? Cause you can't obviously do everything, given the fact that you're maximizing your resources, but you're still a small company. How, how do you decide on what programs, initiatives, collaborators you're gonna go forward with? In terms of what else you would like to expand to, if, you know, given resources and everything else are always possible, given the number of queries I'm sure you probably are seeing. I'll hop back in the queue after that. Thank you. Thanks, Steve. once again, I'll provide some general commentary and turn to Kristen for, for some specifics. you know, when we embarked upon our development plan creation, Kristen and, you know, and her team, as well as, you know, a large number of key opinion leaders who were consulted, came up with a list of, of solid tumors where we felt that the presence of stroma, the lack of a satisfactory outcome, the current standard of care and, and, you know, and also the toxic side effects, all combined to leave an opportunity for an unmet medical need, you know, and an improvement where LSTA1 could make a difference. that's how we've, we've started, you know, and chosen which tumor types to initially work on. We've chosen our partners very, very, simply and pragmatically. We choose people who are not only enthusiastic but who are pragmatic and can actually operate in the clinic. I don't mean physically operate on a patient, but I mean execute in the clinic and get clinical trials done. They can enroll efficiently, effectively, they can follow protocols, and in some cases, they contribute some or all of the capital needed to allow us to move forward in a manner that will advance the development status of the compound from a regulatory perspective, not just provide interesting data to write, you know, medical journal papers. So, you know, that's basically how we've chosen what we're working on and with whom we're working. You know, Kristen can add to that. Also, you know, we have a list of things that we'd like to do, should we find additional resources in the near future that might allow us to do so. Kristen, would you like to add some color, please? Actually, Dave, I think you did a really great job in answering that. I mean, we've described before how we chose the tumor types we've chosen. They're very difficult to treat cancers with hostile tumor microenvironments, with dense stroma, where the standard of care today is just suboptimal. When we explored with key opinion leaders around the world where they felt our technology would work best, we landed on the list of cancers in which we're currently studying. I think, as Dave mentioned, we are picking sites, investigators, et cetera, based on their scientific rigor and understanding that this drug needs to get through registration as soon as possible. Our partners, we ensure that we are doing our drug development in the most capitally efficient way we can, and so we're seeking funding by alternative means and allowing our drug to be exploited both in pancreatic cancer and other solid tumors. Got it. Again, thanks for taking the question and the answers. Thanks. If I may, I'll just add one, one additional commentary, and once again, I'll, I'll, I'll bounce it back to Kristen. When you, when you talked about Steve, you know, how the medical community is reacting and, and, you know, what the level of enthusiasm is, I think Kristen can provide some real insight to that based on her recent visits at the ASCO conference in June. Sure, Dave. We, the team, visited the ASCO conference in June to socialize the BOLSTER trial, which is the solid tumor trial in cholangiocarcinoma, head and neck, and esophageal carcinoma. We had tremendous interest from KOLs across the United States and around the world, including China, wanting to evaluate our product, not only in the BOLSTER trial, but in other trials where they felt this asset would be most effective. It was very heartening to see that the news is getting out, that this drug has the opt- ability to be a platform play, and that we have really interested PIs who are eager to be part of our study. Thank you. Our next question comes from Pete Enderlin with MAZ Partners. Your line is open. Good morning. Thanks for taking my questions, and congratulations on the multiplicity of programs that you're standing up at this point. First question is, does the cash runway that you've projected of close to 11 quarters include some assumption about milestone payments? Good morning, Pete. Thanks. Thanks very much for your kind words. At this point, our cash projections do not include any projections of incoming capital, except perhaps for the remaining available capital for which we are eligible from the New Jersey NOL Program. We are not looking at milestone payments, capital raises, or any other BD or M&A deals in that projection, so it's a very conservative projection. Okay. Over that, close to three-year period, is it possible that there will be some milestone payments, or, or are you just sort of not count... I mean, you're not counting on them, but, but are there ones that could happen in that time frame? Yes, there are. We have, you know, a publicly announced, license deal with Qilu Pharmaceutical in China, which has development and regulatory milestones built into it. There is, I'd say, a reasonable possibility that some of those milestones could be achieved over the course of the next several years. Okay. Then on the transfer of the TPN technology, are there any potential royalties included in that, if such should be possible? I mean, you know, sales eventuate. Yeah, the TPN deal is a, is a, is a typical deal in that we have transferred the, the asset to, you know, another party, which will finance its development, and we've retained a portion of ownership in that, and we expect that we'll also have the ability to achieve, you know, future, you know, benefit from sales and, and other deals should they occur. Other than the ownership portion, would you actually have, and is it written into the agreement that there would be royalties? Off the top of my head, I don't I don't recall that at this point, Pete, but John can get back to you, you know, post-meeting after we go back to the contract. It was just recently signed, and I, I don't recall if it has, you know, specific royalties in it, or if it just starts with the, you know, substantial equity ownership in Impilo. Okay. Can I ask one more, or do you want me to jump back in the queue? Go, go ahead, go ahead and finish up, Pete. Okay. You know, the press release mentioned possible conditional approvals for the ASCEND trial. The question first is, are protocols for conditional approval in various regulatory agencies around the world pretty similar, or, you know, would it vary a lot by, you know, which country you're talking about? Well, you know, in general, you would expect that the medical, you know, scientific results, efficacy and safety, should drive some level of consistency of evaluation and decision in regulatory authorities around the world. In reality, each regulatory authority, whether it be the European Medicines Agency, the Food and Drug Administration, the, the, you know, the TGA in Australia, the, the Chinese authorities, you know, MHLW in Japan, whatever, whatever, they tend to take their own decisions based upon, you know, situations which involve, of course, safety and efficacy. To a certain extent, they have to take into account pharmacoeconomic and even sometimes political considerations within their countries. You know, we would hope that there would be some level of consistency, and we will, of course, explore the opportunity for conditional approvals in all the major registration areas of the world, should that opportunity arise. Does that, I mean, how many different agencies do you contemplate approaching initially for that kind of an, a program? Oh, at least, well, we're going to. We'll, we'll approach the Australian agency, of course. We'll approach the FDA and most likely, eventually, the, the EMA. China, I guess, too, right? Well, well, but, you know, China is being handled by our licensee, Qilu. You know, they'll, they're, they're, they have their own development program, which does include the, the accelerated path, what they call the innovation pathway, contemplation. I think they're pursuing that to the extent that they can as well. Okay. Thank you very much for the information. You're welcome, Pete. I can clarify, right now, the current transfer agreement does not include specifics of royalty. It's just our ownership in the, in the company that would provide us a financial upside, should the product be successful. Okay. Thanks a lot. Okay. Thank you. Our next question will come from Kemp Dolliver with Brookline Capital Markets. Your line is open. Great. Thank you, and good morning. I have two or three questions. You know, quickly, beyond the elimination of the chief business officer position, you know, were there other actions of consequence taken to reduce expenses? Good morning, Kemp. Yes, we, we, we made the, the conscious decision to streamline our efforts in R&D to basically D. Anything that was preclinical, exploratory, or fundamental, you know, supporting what was, was eliminated. We also refined Kristen's clinical operations organization to better suit the execution of the trials that we are doing now in comparison to the trials that we might have been doing, you know, several years ago. Great. There was not any mention of the status of the Morpheus program with Roche. Do you have any incremental insight into the status of the program on their front? Really nothing new since our last quarterly update. At this point, the program remains on hold, pending internal decisions that Roche needs to take, based on, I think, their overall development strategy with atezolizumab. We're just on standby, waiting. Okay, great. You know, my last call or question relates to, you know, cisplatin, and, you know, it had the impact on the BOLSTER trial. You know, I think cisplatin is also being used in the ASCEND trial. That seems to be moving on. You know, can you talk about, you know, whether we should have any concerns about any of your other trials that would use, chemotherapies, or is it really just, limited to, BOLSTER at this point? I believe we're, we, we can say, you know, first of all, with confidence, that cisplatin is not part of the standard of care that's being tested in ASCEND. That's a combination of gemcitabine and nab-paclitaxel, so the cisplatin shortage is not impacting ASCEND. I believe at this point, really, it's just the cholangiocarcinoma arm of BOLSTER that is the major impact. Kristen, is there any other thing that I'm forgetting as it relates to the use of cisplatin in any of our trials? No, you are correct, Dave, and we have procured the cisplatin and to be able to supply our BOLSTER trial. Great. Great. Those are all my questions. Thank you, Kemp. Thank you. This concludes the question and answer session. I'll turn the call back to Dr. Mazzo for closing remarks. Well, again, thank you all for participating in today's call. We look forward to speaking with you again during our next quarterly conference call and to continuing to provide updates on our achievements and progress. We remain grateful for your continued interest and support. Stay well and have a great day. This concludes today's conference call. Thank you for participating. You may now disconnect.